Patents by Inventor Gunther P. Birznieks

Gunther P. Birznieks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Prediction of sleep parameter and response to sleep-inducing compound based on PER3 VNTR genotype
    Patent number: 11845990
    Abstract: The invention relates to the prediction of a sleep parameter (e.g., sleep efficiency (SE), latency to persistent sleep (LPS), wake after sleep onset (WASO), total sleep time (TST)) of an individual and the response of such an individual to a sleep inducing compound based on the individual's PER3 variable number tandem repeat (VNTR) genotype.
    Type: Grant
    Filed: May 21, 2021
    Date of Patent: December 19, 2023
    Assignee: Vanda Pharmaceuticals Inc.
    Inventors: Christian N. Lavedan, Mihael H. Polymeropoulos, Gunther P. Birznieks
  • MELATONIN AGONIST TREATMENT
    Publication number: 20230021493
    Abstract: Melatonin Agonist, MA-1, is administered at effective doses.
    Type: Application
    Filed: October 14, 2022
    Publication date: January 26, 2023
    Inventors: Gunther P. Birznieks, Deepak Phadke, Mihael H. Polymeropoulos
  • PREDICTION OF SLEEP PARAMETER AND RESPONSE TO SLEEP-INDUCING COMPOUND BASED ON PER3 VNTR GENOTYPE
    Publication number: 20210277478
    Abstract: The invention relates to the prediction of a sleep parameter (e.g., sleep efficiency (SE), latency to persistent sleep (LPS), wake after sleep onset (WASO), total sleep time (TST)) of an individual and the response of such an individual to a sleep inducing compound based on the individual's PER3 variable number tandem repeat (VNTR) genotype.
    Type: Application
    Filed: May 21, 2021
    Publication date: September 9, 2021
    Inventors: Christian N. Lavedan, Mihael H. Polymeropoulos, Gunther P. Birznieks
  • MELATONIN AGONIST TREATMENT
    Publication number: 20200397741
    Abstract: Melatonin Agonist, MA-1, is administered at effective doses.
    Type: Application
    Filed: September 1, 2020
    Publication date: December 24, 2020
    Inventors: Gunther P. Birznieks, Deepak Phadke, Mihael H. Polymeropoulos
  • MELATONIN AGONIST TREATMENT
    Publication number: 20180243258
    Abstract: Melatonin Agonist, MA-1, is administered at effective doses.
    Type: Application
    Filed: April 27, 2018
    Publication date: August 30, 2018
    Inventors: Gunther P. Birznieks, Deepak Phadke, Mihael H. Polymeropoulos